Bill Ackman

In the ongoing battle of Bill Ackman versus Herbalife, it appears that Herbalife has struck a decisive blow.
Herbalife was under attack yet again on Friday morning by activist investor Bill Ackman on an appearance on CNBC.
Canaccord Genuity maintained its Buy rating for Herbalife but lowered its price target to $42 from $50, noting that the company is starting to feel like a value trap.
Herbalife reported disappointing third-quarter earnings Monday after the market close, and shares fell on Tuesday.
In the drama of Icahn’s pursuit of eBay in an effort to get it to spin off its PayPal business, the eBay CEO played the part of the mouse to Icahn’s cat.
The longstanding fight between Herbalife and short-selling activist investor Bill Ackman just took yet another odd turn.
Herbalife remains one of the most controversial stocks on Wall Street and Main Street. That controversy is set to come to yet another head on Tuesday, July 22, 2014.
In a sharply worded press release Monday morning, Valeant Pharmaceuticals said that it "can no longer tolerate" statements from Allergan that are "attempts to mislead investors."
Following an appeals court ruling delivered late Monday, Herbalife issued a statement declaring that the decision "validates product consumption as a legitimate measure of demand for multi-level...
Source: ThinkstockHave activist investors gone too far? That is what the news focus may be full of in the coming week. The financial media loves following activist investors like Carl Icahn, Bill...
The specialty pharmaceutical sector is exploding with news of takeovers, exchanges and possible mergers. Here are some of the top stocks started with a rating of Buy at Jefferies.
Source: Courtesy Herbalife Ltd.Shares of Herbalife Ltd. (NYSE: HLF) plunged about 14% on Friday following a Financial Times report that the U.S. Department of Justice and the FBI have each launched...
Source: Courtesy Herbalife Ltd.The Financial Times reported late Friday afternoon that Herbalife Ltd. (NYSE: HLF) is being investigated by both the U.S. Department of Justice and the FBI. Neither...
If Herbalife gets its way, Carl Icahn will soon control five of the company's board seats (slightly more than 38%) while owning just under 17% of its stock. None of the board members being replaced...
Argus has downgraded Herbalife's near-term rating to Hold from Buy. The basis for the call is the recently announced Federal Trade Commission investigation into Herbalife's business practices,...